Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Ульяновский государственный университет», Ульяновск, Россия
Список исп. литературыСкрыть список 1. Bearak J, Popinchalk A, Alkema L, Sedgh G. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health 2018; 6 (4): e380–9. 2. Blumenthal PD, Edelman A. Hormonal contraception. Obstet Gynecol. 2008; 112: 670–84. 3. Bellizzi S, Mannava P, Nagai M, Sobel HL. Reasons for discontinuation of contraception among women with a current unintended pregnancy in 36 low and middle-income countries. Contraception. 2020; 101 (1): 26–33. 4. Piotrowska K, Wang C, Swerdloff RS, Liu PY. Male hormonal contraception: hope and promise. Lancet Diabetes Endocrinol 2017; 5 (3): 214–23. 5. Trussell J. Contraceptive failure in the United States. Contraception 2011; 83 (5): 397–404. 6. Roth MY, Page ST, Bremner WJ. Male hormonal contraception: looking back and moving forward. Andrology. 2016; 4 (1): 4–12. 7. Gava G, Meriggiola MC. Update on male hormonal contraception. Ther Adv Endocrinol Metab. 2019; 10: 2042018819834846. 8. Abbe CR, Page ST, Thirumalai A. Male Contraception. Yale J Biol Med 2020; 93 (4): 603–13. 9. Nieschlag E, Simoni M, Gromoll J, Weinbauer GF. Role of FSH in the regulation of spermatogenesis: clinical aspects. Clin Endocrinol 1999; 51: 139–46. 10. WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 1996; 65 (4): 821–9. 11. Waites GM. Development of methods of male contraception: impact of the World Health Organization Task Force. Fertil Steril. 2003; 80 (1): 1–15. 12. Heckel NJ. Production of oligospermia in a man by the use of testosterone propionate. Proceedings of the Society for Experimental Biology and Medicine. 1939; 40: 658–59. 13. Swerdloff RS, Campfield LA, Palacios A et al. Suppression of human spermatogenesis by depot androgen: potential for male contraception. J Steroid Biochem 1979; 11 (1B): 663–70. 14. Cunningham GR, Silverman VE, Thornby J et al. The potential for an androgen male contraceptive. J Clin Endocrinol Metab 1979; 49 (4): 520–6. 15. McLachlan RI, O'Donnell L, Stanton PG et al. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metab 2002; 87: 546–56. 16. O'Donnell L, Nicholls PK, O'Bryan MK et al. Spermiation: The process of sperm release. Spermatogenesis 2011; 1: 14–35. 17. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet 1990; 336 (8721): 955–9. 18. Nieschlag E. 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. October 22–23, 2006. Contraception. 2007; 75: 166–7. 19. Moreau C, Trussell J, Rodriguez G et al. Contraceptive failure rates in France: results from a population-based survey. Hum Reprod. 2007; 22: 2422–7. 20. Gu YQ, Wang XH, Xu D et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 2003; 88 (2): 562–8. 21. Gu Y, Liang X, Wu W et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 2009; 94: 1910–5. 22. Matthiesson KL, Amory JK, Berger R et al. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 2005; 90 (1): 91–7. 23. Page ST, Amory JK, Anawalt BD et al. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab 2006; 91 (11): 4374–80. 24. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl 1999; 20 (3): 407–14. 25. Bebb RA, Anawalt BD, Christensen RB et al. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 1996; 81: 757–62. 26. Herbst KL, Anawalt BD, Amory JK et al. The male contraceptive regimen of testosterone and levonorgestrel significantly increases lean mass in healthy young men in 4 weeks, but attenuates a decrease in fat mass induced by testosterone alone. J Clin Endocrinol Metab 2003; 88: 1167–73. 27. Anderson RA, Kinniburgh D, Baird DT. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab 2002; 87 (8): 3640–9. 28. Mommers E, Kersemaekers WM, Elliesen J et al. Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2008; 93 (7): 2572–80. 29. Kinniburgh D, Zhu H, Cheng L et al. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod 2002; 17 (6): 1490–501. 30. Kamischke A, Heuermann T, Krüger K et al. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab 2002; 87 (2): 530–9. 31. Meriggiola MC, Costantino A, Saad F et al. Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab 2005; 90 (4): 2005–14. 32. Turner L, Conway AJ, Jimenez M et al. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 2003; 88 (10): 4659–67. 33. Kamischke A, Venherm S, Plöger D et al. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 2001; 86 (1): 303–9. 34. Behre HM, Zitzmann M, Anderson RA et al. Efficacy and safety of an injectable combination hormonal contraceptive for men. J Clin Endocrinol Metab 2016; 101: 4779–88. 35. Yuen F, Nguyen BT, Swerdloff RS, Wang C. Continuing the search for a hormonal male contraceptive. Best Pract Res Clin Obstet Gynaecol 2020; 66: 83–94. 36. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010; 82 (5): 410–7. 37. Mahabadi V, Amory JK, Swerdloff RS et al. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J Clin Endocrinol Metab 2009; 94 (7): 2313–20. 38. Ilani N, Roth MY, Amory JK et al. A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. J Clin Endocrinol Metab 2012; 97 (10): 3476–86. 39. Kumar N, Didolkar AK, Monder C et al. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992; 130 (6): 3677–83. 40. Cummings DE, Kumar N, Bardin CW et al. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab 1998; 83 (12): 4212–9. 41. Von Eckardstein S, Noe G, Brache V et al. International Committee for Contraception Research, The Population Council. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab 2003; 88 (11): 5232–9. 42. Walton MJ, Kumar N, Baird DT et al. 7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. J Androl 2007; 28 (5): 679–88. 43. Heinemann K, Saad F, Wiesemes M et al. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 2005; 20 (2): 549–56. 44. Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology 2006; 147: 3016–26. 45. Attardi BJ, Engbring JA, Gropp D, Hild SA. Development of dimethandrolone 17beta-undecanoate (DMAU) as an oral male hormonal contraceptive: induction of infertility and recovery of fertility in adult male rabbits. J Androl 2011; 32 (5): 530–40. 46. Surampudi P, Page ST, Swerdloff RS et al. Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive. Andrology 2014; 2 (4): 579–87. 47. Thirumalai A, Ceponis J, Amory JK et al. Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill. J Clin Endocrinol Metab 2019; 104 (2): 423–32. 48. Meriggiola MC, Farley TM, Mbizvo MT. A review of androgen-progestin regimens for male contraception. J Androl 2003; 24 (4): 466–83. 49. Eckardstein SV, Schmidt A, Kamischke A et al. CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol (Oxf) 2002; 57: 647–55. 50. Handelsman DJ, Farley TM, Peregoudov A, Waites GM. Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 1995; 63 (1): 125–33. 51. Liu PY, Swerdloff RS, Christenson PD et al. Hormonal Male Contraception Summit Group. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 2006; 367 (9520): 1412–20. 52. Wallace EM, Gow SM, Wu FC. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations. J Clin Endocrinol Metab 1993; 77 (1): 290–3. 53. Yu B, Handelsman DJ. Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia. J Clin Endocrinol Metab 2001; 86: 4406–11.